<p>根據 Oppenheimer &amp; Co. Inc.在最近向 SEC 提交的 13F 表格，該公司在第四季度購買了 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）的新股份。該基金購買了 7,076 股公司股票，價值約為 1,292,000 美元。</p>
<ul>
<li>生物科技正在升温——這兩隻熱門股票脱穎而出</li>
</ul>
<p>其他大型投資者也買賣了該公司的股票。M&amp;T Bank Corp 在第四季度將其在 Axsome Therapeutics 的持股增加了 37.3%。M&amp;T Bank Corp 現在擁有 2,560 股公司股票，價值 467,000 美元，此前在上個季度又購買了 696 股。Pictet Asset Management Holding SA 在第四季度將其在 Axsome Therapeutics 的持倉增加了 20.4%。Pictet Asset Management Holding SA 現在擁有 436,063 股公司股票，價值 79,643,000 美元，此前在上個季度又購買了 73,925 股。UBS Group AG 在第四季度將其在 Axsome Therapeutics 的股份增加了 67.2%。UBS Group AG 現在擁有 355,318 股公司股票，價值 64,895,000 美元，此前在上個季度又購買了 142,867 股。Concurrent Investment Advisors LLC 在第四季度獲得了 Axsome Therapeutics 的新股份，價值約為 300,000 美元。最後，HB Wealth Management LLC 在第四季度將其在 Axsome Therapeutics 的股份增加了 136.7%。HB Wealth Management LLC 現在擁有 34,102 股公司股票，價值 6,228,000 美元，此前在上個季度又購買了 19,696 股。81.49% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<h2>Axsome Therapeutics 新聞匯總</h2>
<p>以下是本週影響 Axsome Therapeutics 的關鍵新聞：</p>
<ul>
<li>積極情緒：強勁的商業吸引力——Axsome 報告第一季度產品收入為 1.912 億美元，同比增長約 57%，得益於 AUVELITY 和 SUNOSI，這支持了公司的增長敍述和近期現金生成。閲讀更多。</li>
<li>積極情緒：分析師樂觀和目標價上調——多家機構提高了目標價（尤其是瑞穗證券至 310 美元，富國銀行至 255 美元，貝爾德等），覆蓋仍然偏向積極，這可以支持上漲勢頭和買入興趣。閲讀更多。</li>
<li>中性情緒：管理層外聯安排——Axsome 將參加 5 月的投資者會議（包括美銀的爐邊聊天），提供額外的投資者接觸，但不確定立即影響。閲讀更多。</li>
<li>中性情緒：財報細節和電話會議記錄可用——分析師正在解析電話會議和指導的影響；更深入的閲讀可能會解決關於銷售節奏和費用軌跡的問題。閲讀更多。</li>
<li>消極情緒：盈利未達預期——GAAP 每股收益為（1.26 美元），未達到市場共識（約 0.85 美元的虧損），負毛利率/股本回報率突顯了近期盈利能力和成本結構的擔憂，儘管收入強勁。閲讀更多。</li>
<li>消極情緒：內部人士出售——首席運營官 Mark Jacobson 披露了銷售（5 月 4 日的大宗交易和 5 月 5 日的小額交易），這可能會引發短期情緒問題，儘管報告者表示仍持有股份。閲讀更多。</li>
<li>消極情緒：耐久性擔憂——一些分析師/評論員質疑連續產品銷售趨勢和峯值收入假設的可實現性，這可能會抑制多重擴張，除非有更明確的毛利改善。閲讀更多。</li>
</ul>
<h2>分析師評級變動</h2>
<ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
<p>幾家研究公司最近對 AXSM 發表了看法。Jefferies Financial Group 將 Axsome Therapeutics 的目標價從 245.00 美元上調至 275.00 美元，並在週一的報告中給予該公司 “買入” 評級。Cantor Fitzgerald 在週一的研究報告中重新發布了 “增持” 評級，並設定了 272.00 美元的目標價。Truist Financial 在 3 月 25 日的研究報告中將 Axsome Therapeutics 的評級提升至 “強力買入”。Oppenheimer 在週一的研究報告中設定了 280.00 美元的目標價。最後，Needham &amp; Company LLC 將 Axsome Therapeutics 的目標價從 225.00 美元上調至 255.00 美元，並在週二的報告中給予該股票 “買入” 評級。一位研究分析師給予該股票 “強力買入” 評級，十八位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為 251.26 美元。</p>
<p><strong>查看我們最新的 AXSM 股票報告</strong></p>
<h2>Axsome Therapeutics 股價下跌 0.2%</h2>
<ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
<p>NASDAQ:AXSM 週四開盤價為 222.63 美元。Axsome Therapeutics, Inc.的 52 周低點為 96.09 美元，52 周高點為 234.29 美元。該公司的債務與股本比率為 2.27，速動比率為 1.48，流動比率為 1.39。該公司的 50 日移動平均線為 172.69 美元，200 日移動平均線為 164.03 美元。該公司的市值為 114.6 億美元，市盈率為-59.69，貝塔值為 0.59。</p>
<p>Axsome Therapeutics（NASDAQ:AXSM - 獲取免費報告）最後一次公佈財報是在 5 月 4 日，週一。該公司報告本季度每股收益為（1.26 美元），未達到分析師的共識預期（0.85 美元的虧損），差距為（0.41 美元）。該公司本季度的收入為 1.912 億美元，而市場共識預期為 1.911 億美元。Axsome Therapeutics 的股本回報率為負 267.16%，淨利潤率為負 26.59%。Axsome Therapeutics 的收入同比增長 57.4%。股票分析師預計 Axsome Therapeutics, Inc.在本年度將發佈-1.19 的每股收益。</p>
<h2>Axsome Therapeutics 的內部交易</h2>
<p>在其他新聞中，內部人士 Ari Maizel 在 2023 年 4 月 22 日的交易中出售了 7,500 股公司的股票。股票的平均售價為 182.42 美元，總價值為 1,368,150.00 美元。交易後，該內部人士直接持有 7,500 股公司股票，價值為 1,368,150 美元。此次交易使其持股減少了 50.00%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，首席運營官 Mark L. Jacobson 在 2023 年 2 月 26 日的交易中出售了 35,378 股公司的股票。這些股票的平均售價為 161.88 美元，總價值為 5,726,990.64 美元。關於此次出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 72,628 股公司股票，價值為 12,205,662 美元。公司內部人士持有 20.60% 的公司股票。</p>
<h2>關於 Axsome Therapeutics</h2>
<p>（免費報告）</p>
<p>Axsome Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於開發針對中樞神經系統（CNS）疾病的新療法。該公司專注於小分子藥物，旨在滿足抑鬱症、偏頭痛、嗜睡症和纖維肌痛等領域的未滿足醫療需求。Axsome 採用精準醫學的方法，利用藥理創新來針對疾病的潛在機制，提高患者的治療效果。</p>
<p>Axsome 的產品管線包括多個晚期和已批准的產品候選者。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比 Axsome Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
<p>在你考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
<p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AXSM

<p>Oppenheimer & Co. Inc. 在第四季度新建了 Axsome Therapeutics 的持倉，購買了 7,076 股，價值約 129 萬美元。其他投資者，包括 M&T Bank Corp 和 UBS Group AG，也增加了對該公司的投資。儘管收入增長強勁，Axsome 仍面臨盈利未達預期和內部人士拋售等挑戰，這可能影響投資者情緒。分析師們依然樂觀，多位分析師上調了目標價，並維持對該股票的積極評級，該股票的共識評級為 “適度買入”</p>

<p>Oppenheimer &amp; Co. Inc. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 7,076 shares of the company's stock, valued at approximately $1,292,000.</p>
<div class="lb-trans"><p>根據 Oppenheimer &amp; Co. Inc.在最近向 SEC 提交的 13F 表格，該公司在第四季度購買了 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）的新股份。該基金購買了 7,076 股公司股票，價值約為 1,292,000 美元。</p>
</div><ul>
<li>Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技正在升温——這兩隻熱門股票脱穎而出</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. M&amp;T Bank Corp lifted its holdings in shares of Axsome Therapeutics by 37.3% in the fourth quarter. M&amp;T Bank Corp now owns 2,560 shares of the company's stock worth $467,000 after acquiring an additional 696 shares during the last quarter. Pictet Asset Management Holding SA increased its position in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company's stock worth $79,643,000 after purchasing an additional 73,925 shares in the last quarter. UBS Group AG lifted its stake in Axsome Therapeutics by 67.2% in the 4th quarter. UBS Group AG now owns 355,318 shares of the company's stock valued at $64,895,000 after purchasing an additional 142,867 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in Axsome Therapeutics in the fourth quarter valued at approximately $300,000. Finally, HB Wealth Management LLC grew its stake in shares of Axsome Therapeutics by 136.7% during the fourth quarter. HB Wealth Management LLC now owns 34,102 shares of the company's stock worth $6,228,000 after buying an additional 19,696 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者也買賣了該公司的股票。M&amp;T Bank Corp 在第四季度將其在 Axsome Therapeutics 的持股增加了 37.3%。M&amp;T Bank Corp 現在擁有 2,560 股公司股票，價值 467,000 美元，此前在上個季度又購買了 696 股。Pictet Asset Management Holding SA 在第四季度將其在 Axsome Therapeutics 的持倉增加了 20.4%。Pictet Asset Management Holding SA 現在擁有 436,063 股公司股票，價值 79,643,000 美元，此前在上個季度又購買了 73,925 股。UBS Group AG 在第四季度將其在 Axsome Therapeutics 的股份增加了 67.2%。UBS Group AG 現在擁有 355,318 股公司股票，價值 64,895,000 美元，此前在上個季度又購買了 142,867 股。Concurrent Investment Advisors LLC 在第四季度獲得了 Axsome Therapeutics 的新股份，價值約為 300,000 美元。最後，HB Wealth Management LLC 在第四季度將其在 Axsome Therapeutics 的股份增加了 136.7%。HB Wealth Management LLC 現在擁有 34,102 股公司股票，價值 6,228,000 美元，此前在上個季度又購買了 19,696 股。81.49% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><h2>Axsome Therapeutics News Roundup</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 新聞匯總</h2>
</div><p>Here are the key news stories impacting Axsome Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本週影響 Axsome Therapeutics 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: Strong commercial traction — Axsome reported Q1 product revenue of $191.2M, up ~57% year‑over‑year driven by AUVELITY and SUNOSI, which supports the company’s growth narrative and near‑term cash generation. Read More.</li>
<li>Positive Sentiment: Analyst optimism and price‑target lifts — multiple firms raised targets (notably Mizuho to $310, Wells Fargo to $255, Baird and others), and coverage remains skewed positive, which can support upside momentum and bid interest. Read More.</li>
<li>Neutral Sentiment: Management outreach scheduled — Axsome will participate in May investor conferences (including a BofA fireside chat), offering additional investor access but uncertain immediate impact. Read More.</li>
<li>Neutral Sentiment: Earnings detail and call transcript available — analysts are parsing the conference call and guidance implications; deeper read may resolve questions around sales cadence and expense trajectory. Read More.</li>
<li>Negative Sentiment: Profitability miss — GAAP EPS of ($1.26) missed consensus (~$0.85 loss), and negative margins/ROE highlight near‑term profitability and cost structure concerns despite revenue strength. Read More.</li>
<li>Negative Sentiment: Insider selling — COO Mark Jacobson disclosed sales (large blocks on May 4 and a smaller sale May 5), which may raise short‑term sentiment questions even though filers report remaining holdings. Read More.</li>
<li>Negative Sentiment: Durability concerns — some analysts/commentators question sequential product sales trends and achievability of peak revenue assumptions, which could temper multiple expansion absent clearer margin improvements. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：強勁的商業吸引力——Axsome 報告第一季度產品收入為 1.912 億美元，同比增長約 57%，得益於 AUVELITY 和 SUNOSI，這支持了公司的增長敍述和近期現金生成。閲讀更多。</li>
<li>積極情緒：分析師樂觀和目標價上調——多家機構提高了目標價（尤其是瑞穗證券至 310 美元，富國銀行至 255 美元，貝爾德等），覆蓋仍然偏向積極，這可以支持上漲勢頭和買入興趣。閲讀更多。</li>
<li>中性情緒：管理層外聯安排——Axsome 將參加 5 月的投資者會議（包括美銀的爐邊聊天），提供額外的投資者接觸，但不確定立即影響。閲讀更多。</li>
<li>中性情緒：財報細節和電話會議記錄可用——分析師正在解析電話會議和指導的影響；更深入的閲讀可能會解決關於銷售節奏和費用軌跡的問題。閲讀更多。</li>
<li>消極情緒：盈利未達預期——GAAP 每股收益為（1.26 美元），未達到市場共識（約 0.85 美元的虧損），負毛利率/股本回報率突顯了近期盈利能力和成本結構的擔憂，儘管收入強勁。閲讀更多。</li>
<li>消極情緒：內部人士出售——首席運營官 Mark Jacobson 披露了銷售（5 月 4 日的大宗交易和 5 月 5 日的小額交易），這可能會引發短期情緒問題，儘管報告者表示仍持有股份。閲讀更多。</li>
<li>消極情緒：耐久性擔憂——一些分析師/評論員質疑連續產品銷售趨勢和峯值收入假設的可實現性，這可能會抑制多重擴張，除非有更明確的毛利改善。閲讀更多。</li>
</ul>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
</div><p>Several research firms recently weighed in on AXSM. Jefferies Financial Group raised their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and set a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday. Truist Financial raised Axsome Therapeutics to a &#34;strong-buy&#34; rating in a research note on Wednesday, March 25th. Oppenheimer set a $280.00 target price on shares of Axsome Therapeutics in a research report on Monday. Finally, Needham &amp; Company LLC boosted their target price on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $251.26.</p>
<div class="lb-trans"><p>幾家研究公司最近對 AXSM 發表了看法。Jefferies Financial Group 將 Axsome Therapeutics 的目標價從 245.00 美元上調至 275.00 美元，並在週一的報告中給予該公司 “買入” 評級。Cantor Fitzgerald 在週一的研究報告中重新發布了 “增持” 評級，並設定了 272.00 美元的目標價。Truist Financial 在 3 月 25 日的研究報告中將 Axsome Therapeutics 的評級提升至 “強力買入”。Oppenheimer 在週一的研究報告中設定了 280.00 美元的目標價。最後，Needham &amp; Company LLC 將 Axsome Therapeutics 的目標價從 225.00 美元上調至 255.00 美元，並在週二的報告中給予該股票 “買入” 評級。一位研究分析師給予該股票 “強力買入” 評級，十八位給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “適度買入”，共識目標價為 251.26 美元。</p>
</div><p><strong>View Our Latest Stock Report on AXSM</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 AXSM 股票報告</strong></p>
</div><h2>Axsome Therapeutics Trading Down 0.2%</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 股價下跌 0.2%</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
</div><p>NASDAQ:AXSM opened at $222.63 on Thursday. Axsome Therapeutics, Inc. has a 52 week low of $96.09 and a 52 week high of $234.29. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.48 and a current ratio of 1.39. The firm's fifty day moving average is $172.69 and its 200-day moving average is $164.03. The firm has a market cap of $11.46 billion, a P/E ratio of -59.69 and a beta of 0.59.</p>
<div class="lb-trans"><p>NASDAQ:AXSM 週四開盤價為 222.63 美元。Axsome Therapeutics, Inc.的 52 周低點為 96.09 美元，52 周高點為 234.29 美元。該公司的債務與股本比率為 2.27，速動比率為 1.48，流動比率為 1.39。該公司的 50 日移動平均線為 172.69 美元，200 日移動平均線為 164.03 美元。該公司的市值為 114.6 億美元，市盈率為-59.69，貝塔值為 0.59。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.Axsome Therapeutics's revenue was up 57.4% compared to the same quarter last year. Equities analysts expect that Axsome Therapeutics, Inc. will post -1.19 earnings per share for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（NASDAQ:AXSM - 獲取免費報告）最後一次公佈財報是在 5 月 4 日，週一。該公司報告本季度每股收益為（1.26 美元），未達到分析師的共識預期（0.85 美元的虧損），差距為（0.41 美元）。該公司本季度的收入為 1.912 億美元，而市場共識預期為 1.911 億美元。Axsome Therapeutics 的股本回報率為負 267.16%，淨利潤率為負 26.59%。Axsome Therapeutics 的收入同比增長 57.4%。股票分析師預計 Axsome Therapeutics, Inc.在本年度將發佈-1.19 的每股收益。</p>
</div><h2>Insider Transactions at Axsome Therapeutics</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 的內部交易</h2>
</div><p>In other news, insider Ari Maizel sold 7,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company's stock, valued at $1,368,150. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 35,378 shares of the company's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $161.88, for a total value of $5,726,990.64. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 72,628 shares of company stock valued at $12,205,662. Corporate insiders own 20.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Ari Maizel 在 2023 年 4 月 22 日的交易中出售了 7,500 股公司的股票。股票的平均售價為 182.42 美元，總價值為 1,368,150.00 美元。交易後，該內部人士直接持有 7,500 股公司股票，價值為 1,368,150 美元。此次交易使其持股減少了 50.00%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，首席運營官 Mark L. Jacobson 在 2023 年 2 月 26 日的交易中出售了 35,378 股公司的股票。這些股票的平均售價為 161.88 美元，總價值為 5,726,990.64 美元。關於此次出售的 SEC 文件提供了更多信息。在過去的九十天裏，內部人士共出售了 72,628 股公司股票，價值為 12,205,662 美元。公司內部人士持有 20.60% 的公司股票。</p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>關於 Axsome Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc 是一家臨牀階段的生物製藥公司，致力於開發針對中樞神經系統（CNS）疾病的新療法。該公司專注於小分子藥物，旨在滿足抑鬱症、偏頭痛、嗜睡症和纖維肌痛等領域的未滿足醫療需求。Axsome 採用精準醫學的方法，利用藥理創新來針對疾病的潛在機制，提高患者的治療效果。</p>
</div><p>Axsome's pipeline includes several late-stage and approved product candidates.</p>
<div class="lb-trans"><p>Axsome 的產品管線包括多個晚期和已批准的產品候選者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Axsome Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Oppenheimer & Co. Inc. Takes $1.29 Million Position in Axsome Therapeutics, Inc. $AXSM

Market Beat

Axsome Therap

奧本海默控股

M&T Bank

瑞銀集團

瑞穗金融集團

Mizuho Financial Group, Inc.

富國銀行

美國銀行

Jefferies Financial

Truist Financial

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Oppenheimer & Co. Inc. 在 Axsome Therapeutics, Inc. $AXSM 中建立了價值 129 萬美元的頭寸